Pharmaceuticals 'not doing enough' to develop new antibiotics
Pharmaceutical companies are not doing enough to develop new antibiotics following an increase in antibiotic-resistant infections worldwide, said Dr Jason Clark, Chief Technology Officer of Novolytics.
Speaking exclusively to the Information Daily at Global Health 2013: Rise of the Resistance, Dr Clark explained how Novolytics aims to exploit the therapeutic potential offered by bacteriophages (“phages”) in a way which is commercially viable and attractive to its investors.
A bacteriophage is a virus that infects bacteria and is seen as a possible future treatment against strains of antibiotic-resistant infections. It is understood that phages kill one quarter of the bacteria on the planet every day.
Dr Clark said: “Bacteriophages are everywhere. They're on your skin, in your food, phages are in your stomach, you probably have more phages in your body than you do bacteria and they're completely inert in humans and other mammals so they're very safe”.
Dr Clark explained precisely how his company is treating antibiotic resistant infections: “At our company we use bacteriophages to treat antibiotic resistant infections, bacteria phages are viruses which only infect bacteria, what they do is infect and kill bacteria such as MRSA and E coli”.
Right now the company are in the stages of research just before Phase 1 clinical trials. All three phases of the clinical trials would take almost ten years to be completed, even though phases 1 and 2 are relatively quick.
“There’s quite a large body of literature suggesting that they are very safe and that they do work, the issue is that they have not been purified in a manner that’s consistent with western regulatory standards.
"They have not been taken through the full clinical trials process and that’s what we are trying to do", said Dr Clark.
If you enjoyed reading the story, register HERE to receive daily email alerts on public policy and public sector service delivery. Follow us @TheInfoDaily and @HCIDAILY for all your health policy needs.